New approach tries to outsmart aggressive skin cancer
NCT ID NCT03543969
Summary
This small, early study is testing a flexible treatment schedule for people with advanced melanoma that has a specific genetic change (BRAF mutation). It combines two drugs that target the cancer's growth signals with an immunotherapy drug that helps the immune system fight the cancer. The goal is to see if turning the targeted drugs on and off based on blood tests can better control the cancer and manage side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.